Opinion
Video
Dr Louise Kostos discusses combination therapies in mHSPC
Author(s):
"It was a really interesting paper to develop and write, because over the past decade, there's been such a paradigm shift in the treatment of prostate cancer," says Dr Louise Kostos.
In this video, Dr Louise Kostos provides an overview of the European Urology paper “Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.” Kostos is a medical oncologist and PhD candidate at Peter MacCallum Cancer Centre in Victoria, Australia.
Transcription:
Please provide an overview of this paper and its notable findings.
Myself, along with a group of global leaders in prostate cancer—in particular, this paper was led by Professors Arun Azad and Karim Fizazi—we got together and hopefully developed what is a comprehensive review of the data surrounding combination therapies in prostate cancer, in particular in the locally advanced setting and also in the metastatic hormone-sensitive prostate cancer setting. We recently published this narrative review in European Urology. I guess it was a really interesting paper to develop and write, because over the past decade, there's been such a paradigm shift in the treatment of prostate cancer, and there's been so many changes. Ten years ago, we really just had ADT for metastatic hormone-sensitive prostate cancer, and now, as you know, there's an array of treatments. I think the most notable finding, which we do focus on, is we now have a new standard of care for metastatic hormone-sensitive prostate cancer, which is a doublet with an ADT backbone and an androgen receptor pathway inhibitor or an ARPI. We do focus on the data supporting that, but we also touch on who should perhaps get a triplet regimen with the addition of docetaxel. We touch on similar therapies that have been evaluated earlier on in the locally advanced setting. We also do touch on all of the emerging novel treatments and combinations that are being evaluated in clinical trials. I think these really highlight that this is still a very rapidly evolving field, and we will continue to see changes in the coming years as those trials read out.
This transcript was AI generated and edited by human editors for clarity.
